{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:10:08Z","timestamp":1781712608178,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.disamonth.2025.101967","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T23:36:11Z","timestamp":1750462571000},"page":"101967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome"],"prefix":"10.1016","volume":"71","author":[{"given":"David P.","family":"Randall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ncl.2018.01.008","article-title":"Lambert-Eaton Myasthenic Syndrome","volume":"36","author":"Kesner","year":"2018","journal-title":"Neurol Clin"},{"issue":"6","key":"10.1016\/j.disamonth.2025.101967_bib0002","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1212\/CON.0000000000001205","article-title":"Lambert-Eaton Myasthenic Syndrome and Botulism","volume":"28","author":"Raja","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"12","key":"10.1016\/j.disamonth.2025.101967_bib0003","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ncl.2018.01.009","article-title":"Practical Anatomy of the Neuromuscular Junction in Health and Disease","volume":"36","author":"Nishimune","year":"2018","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.disamonth.2025.101967_bib0006","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1060028019864574","article-title":"Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: a New Take on an Old Drug","volume":"54","author":"Yoon","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0007","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1590\/0004-282x20170194","article-title":"Lambert-Eaton myasthenic syndrome: the 60th anniversary of Eaton and Lambert's pioneering article","volume":"76","author":"Lorenzoni","year":"2018","journal-title":"Arq Neuropsiquiatr"},{"issue":"9","key":"10.1016\/j.disamonth.2025.101967_bib0008","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00415-017-8541-9","article-title":"Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2025.101967_bib0009","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/CON.0000000000000415","article-title":"Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome","volume":"22","author":"Nicolle","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.disamonth.2025.101967_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10072-014-1637-4","article-title":"Italian Working Group on Myasthenic Syndromes. Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management","volume":"35","author":"Evoli","year":"2014","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.disamonth.2025.101967_bib0011","first-page":"437","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.disamonth.2025.101967_bib0012","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/PPA.S292462","article-title":"Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life","volume":"15","author":"Epstein","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.disamonth.2025.101967_bib0013","doi-asserted-by":"crossref","first-page":"293","DOI":"10.12998\/wjcc.v3.i3.293","article-title":"Voltage gated calcium channel antibody-related neurological diseases","volume":"3","author":"Bekircan-Kurt","year":"2015","journal-title":"World J Clin Cases"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0014","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1759-7714.13290","article-title":"Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: a case report","volume":"11","author":"Li","year":"2020","journal-title":"Thorac Cancer"},{"issue":"21","key":"10.1016\/j.disamonth.2025.101967_bib0015","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1212\/WNL.0b013e318293e14e","article-title":"Child neurology: diagnosis of Lambert-Eaton myasthenic syndrome in children","volume":"80","author":"Morgan-Followell","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-245773","article-title":"Lambert-Eaton myasthenic syndrome in a young girl","volume":"15","author":"Moor","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.disamonth.2025.101967_bib0017","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/WCO.0000000000000972","article-title":"Neuromuscular junction disorders beyond myasthenia gravis","volume":"34","author":"Oh","year":"2021","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00004311-200604420-00007","article-title":"Acquired disorders of the neuromuscular junction","volume":"44","author":"O'Neill","year":"2006","journal-title":"Int Anesthesiol Clin"},{"issue":"22","key":"10.1016\/j.disamonth.2025.101967_bib0019","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2025.101967_bib0020","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1212\/CON.0000000000000807","article-title":"Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis","volume":"25","author":"Guidon","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/j.disamonth.2025.101967_bib0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02329922","article-title":"Autonomic dysfunction in Lambert-Eaton myasthenic syndrome","volume":"11","author":"Waterman","year":"2001","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.disamonth.2025.101967_bib0022","article-title":"Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis"},{"issue":"1","key":"10.1016\/j.disamonth.2025.101967_bib0023","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12883-024-03983-8","article-title":"Late onset cerebellar ataxia syndrome after non-paraneoplastic Lambert-Eaton myasthenic syndrome: a case study","volume":"25","author":"Randall","year":"2025","journal-title":"BMC Neurol"},{"issue":"1\u20132","key":"10.1016\/j.disamonth.2025.101967_bib0024","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jns.2008.02.004","article-title":"Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"270","author":"Lorenzoni","year":"2008","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mus.21315","article-title":"Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction","volume":"40","author":"Pellkofer","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.disamonth.2025.101967_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26079","article-title":"Lambert-Eaton myasthenic syndrome and cerebellar ataxia: is Response to immunotherapy a clue to pathogenesis?","author":"Ambrose","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.disamonth.2025.101967_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pediatrneurol.2016.06.004","article-title":"Voltage-Gated P\/Q-Type Calcium Channel Antibodies Associated With Cerebellar Degeneration","volume":"62","author":"Spiciarich","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.disamonth.2025.101967_bib0028","first-page":"731","article-title":"Myasthenia gravis Lambert-Eaton overlap syndrome: recommended modification for the diagnostic criteria","volume":"70","author":"Oh","year":"2024","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.disamonth.2025.101967_bib0029","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.disamonth.2025.101967_bib0030","first-page":"31","article-title":"The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma","volume":"2","author":"Briggs","year":"2013","journal-title":"Immunotargets Ther."},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0031","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5414\/NP301282","article-title":"Muscular pathological features in patients with Lambert-Eaton myasthenic syndrome associated with small cell lung carcinoma","volume":"40","author":"Zhang","year":"2021","journal-title":"Clin Neuropathol"},{"issue":"7","key":"10.1016\/j.disamonth.2025.101967_bib0032","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.disamonth.2025.101967_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67571-9","article-title":"Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort","volume":"10","author":"Maddison","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.disamonth.2025.101967_bib0034","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.disamonth.2025.101967_bib0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ncl.2020.09.007","article-title":"Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome","volume":"39","author":"Bodkin","year":"2021","journal-title":"Neurol Clin"},{"issue":"5","key":"10.1016\/j.disamonth.2025.101967_bib0037","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/WCO.0b013e32833cc968","article-title":"Autoimmune mediated neuromuscular junction defects","volume":"23","author":"Farrugia","year":"2010","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.disamonth.2025.101967_bib0038","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/mus.26052","article-title":"Jacobus DP; Dapper Study Team. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia","volume":"57","author":"Sanders","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.disamonth.2025.101967_bib0039","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3988\/jcn.2024.0018","article-title":"Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome","volume":"20","author":"Oh","year":"2024","journal-title":"J Clin Neurol"},{"issue":"2","key":"10.1016\/j.disamonth.2025.101967_bib0040","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2011","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001150292500121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001150292500121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T13:09:55Z","timestamp":1754572195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001150292500121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S001150292500121X"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.101967","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.101967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101967"}}